Results: Although the absence of FcRg did not affect production of the immunoglobulin, the clinical skin severity scores were lower in FcRg -/-NC/Tnd mice by half than in conventional WT mice. On the other hand, there were no differences in both scratching behavior elicited by dermatitis and Th1/Th2 cytokine production between 2 groups of mice. In the skin lesion of FcRg null mice, mild epidermal hyperplasia and immune cell infiltration were observed. Particularly, mast cell numbers and their degranulation were significantly decreased in the skin of FcRg-deficient mice. Conclusions: FcRg was not critical to the onset of AD, because FcRg-deficient mice exhibited moderate dermatitis and scratching behavior comparable to WT. On the other hand, although scratching behavior induced the mechanical destruction of skin barriers and mast cell activation, the absence of FcRg markedly attenuated the skin severity, immune cell recruitment including lymphocytes, and mast cell degranulation. These results indicated that the FcRg-mediated immune response by specific IgG and IgE regulate the exacerbation of clinical symptoms in AD. Background: To determine the frequency of patients (pts) with autoimmune diseases who developed stroke and to analyse the associated risk factors. Methods: We made a retrospective analysis of 251 pts with stroke, hospitalized during 1 year period at the Department for Urgent Neurology. Of them, we selected 7 pts with a history of autoimmune diseases. Results: Three patients had systemic lupus erythematosus (SLE), 2 pts had M. Behcet, one patient was diagnosed with Sneddon sy and one patient had Vascullitis allergica leucocytoclastica. All pts were females, except one male pt with M. Behcet. The average age was 49 6 11 years. Two patients with massive ischemic stroke had a lethal outcome. Hypertension was found as an independent risk factor for stroke in all pts (P , 0.01). Other risk factors included chronic renal failure, antiphospholipid antibodies, hypercoagulable state and symptomatic seizures. Conclusions: The incidence of autoimmune diseases in patients with stroke was 2.7% in our material. Hypertension was an independent risk factor for subsequent stroke. Osaka University Graduate School of Frontier Biosciences, Suita City, Japan. Background: A humanized anti-interleukin-6 receptor, tocilizumab, has been approved as a biological drug for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis and Castleman's disease. Since dysregulation of IL-6 production also plays a pathologic role in other various autoimmune and allergic diseases, we tested whether tocilizumab might have beneficial effect on refractory autoimmune or allergic diseases to conventional treatment regimens. Methods: After informed consent by patients and approval by the Ethics Committee of Osaka University Hospital were obtained, patients were treated with tocilizumab at 8 mg/kg every 4 weeks. Results: The diseases for which off-label use of tocililizumab was performed included amyloid A amyloidosis, relapsing polychondritis, systemic sclerosis, HLA-B27 positive spondyloarthritis such as reactive arthritis and psoriatic arthritis, polymyalgia rheumatica and polymyositis. After 3 injections of tocilizumab amyloid fibril deposits in the colon disappeared in a patient with gastrointestinal AA amyloidosis, who was resistant to anti-TNF drugs and disease-modifying antirheumatic drugs. In 2 patients with refractory relapsing polychondritis, the continuous tocilizumab treatment for more than 3 years could ameliorate clinical symptoms related to upper and lower airways and stabilize the disease activity. The skin sclerosis of 2 patients with systemic sclerosis became softened with reductions of 52 and 23% in the modified Rodnan total skin score by the tocilizumab treatment. Two administrations of tocilizumab led to the disappearance of joint swelling, pain and complete resolution of symptoms in a patient with refractory reactive arthritis to several therapeutic regimens for 4 years, whereas 2 patients with severe psoriatic arthritis did hardly respond to tocilizumab. In a patient with polymyalgia rheumatica, the tocilizumab treatment caused a reduction of the disease activity score (PMR-AS) from 22.14 to 0.74, indicating remission. Creatine phosphokinase normalized by 2 patients with polymyositis who had been resistant to corticosteroids and immunosuppressive drugs, in association with the disappearance of the high intensity zones in the thigh muscles on MR images. Conclusions: These clinical effects of tocilizumab suggest that it may be an optional treatment for refractory autoimmune or allergic diseases although further clinical trails will be essential. 3 Research Institute of pediatrics and pediatric surgery, Moscow, Russia. Background: Atopic dermatitis (AD) is a chronic skin disease predominately with the beginning in childhood. One hundred autoantigens and more are capable of binding with autoantibodies in AD patients, including autoantigens with common epitopes of EBV. Aim of study was to reveal IgE-and IgGautoreactivity to some tissue proteins and IgG-abs to some herpes viruses and to compare the received dates with the severity of AD. Methods: In the sera of 157 children with AD (from 1 to 17 years old) the levels of IgG-and IgE-abs to keratin, collagen III and VI, elastin, myosin and basic myelin protein were determined in adapted ELISA. The levels of IgGabs to HSV, CMV and EBV were determined using commercial kit of ELISA. The level of total IgE and IgE-antibodies to allergens were detected using an autoanalyzer. Results: In all age groups of patients (with light AD, middle AD and severe AD) elevated levels of total IgE were revealed, especially in children with severe AD (Me ¼ 360 KU/L (80 -1160); P , 0.05). An increased contents of IgE-abs to keratin (Me ¼ 2.71 ME/mL (1.4-13.69); P , 0.05) and elastin (Me ¼ 2.69 ME/mL (1.4-2.78); P , 0.05) and IgG-abs to keratin (Me ¼ 296.21 mg/mL (127.88-342.01); P , 0.05) were revealed in children with severe AD in comparison with healthy children. Whereas in children with light AD the levels of these antibodies were not significantly increased (P . 0.05), but were being increased in proportion to a severity of AD. We revealed a correlation between the levels of total IgE and the levels of IgE-abs
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